Central vascular access devices in oncology and hematology considered from a different point of view: how do patients experience their vascular access ports?
- PMID: 15684906
- DOI: 10.1097/00129804-200501000-00008
Central vascular access devices in oncology and hematology considered from a different point of view: how do patients experience their vascular access ports?
Abstract
Background: Oncology patients require long-term vascular access, but the subjective experience of having a port in daily life is not well studied.
Methods: In a prospective study, patients at an outpatient clinic filled out a questionnaire.
Instrument: The questionnaire consisted of four questions.
Results: The top three reported benefits of having a port were (1) no more peripheral venipunctures, (2) greater convenience, and (3) arms left free for activities of daily living. Patients disliked the visibility of ports and complained about site soreness.
Conclusions: Good nursing care includes the ability to provide optimal care and maintenance of the vascular access device, but understanding the patients' point of view is an added value.
Similar articles
-
Port navigation: let the journey begin.Clin J Oncol Nurs. 2007 Aug;11(4):485-8. doi: 10.1188/07.CJON.485-488. Clin J Oncol Nurs. 2007. PMID: 17723960 Review.
-
Totally implantable venous access ports--the patients' point of view. A quality control study.Cancer Nurs. 1992 Oct;15(5):378-81. Cancer Nurs. 1992. PMID: 1423257
-
Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: a qualitative study.BMJ Open. 2019 Jul 9;9(7):e026077. doi: 10.1136/bmjopen-2018-026077. BMJ Open. 2019. PMID: 31292176 Free PMC article.
-
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device.Eur J Cancer. 1997 Jul;33(8):1190-4. doi: 10.1016/s0959-8049(97)00039-7. Eur J Cancer. 1997. PMID: 9301441 Clinical Trial.
-
Insertion and placement of central catheters in the oncology patient.Semin Oncol Nurs. 2010 May;26(2):102-12. doi: 10.1016/j.soncn.2010.02.004. Semin Oncol Nurs. 2010. PMID: 20434643 Review.
Cited by
-
Improving cancer patients' knowledge about totally implantable access port: a randomized controlled trial.Support Care Cancer. 2016 Feb;24(2):833-841. doi: 10.1007/s00520-015-2851-1. Epub 2015 Jul 24. Support Care Cancer. 2016. PMID: 26201750 Clinical Trial.
-
Patient reported outcome and experience measures among patients with central venous access devices: a systematic review.Support Care Cancer. 2024 Nov 5;32(12):775. doi: 10.1007/s00520-024-08961-x. Support Care Cancer. 2024. PMID: 39499376
-
Tailored approach to the choice of long-term vascular access in breast cancer patients.PLoS One. 2021 Jul 22;16(7):e0255004. doi: 10.1371/journal.pone.0255004. eCollection 2021. PLoS One. 2021. PMID: 34293064 Free PMC article.
-
Totally implantable vascular access devices 30 years after the first procedure. What has changed and what is still unsolved?Support Care Cancer. 2014 Jun;22(6):1705-14. doi: 10.1007/s00520-014-2208-1. Support Care Cancer. 2014. PMID: 24659216 Review.
-
Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial.Asia Pac J Oncol Nurs. 2022 May 21;9(9):100085. doi: 10.1016/j.apjon.2022.100085. eCollection 2022 Sep. Asia Pac J Oncol Nurs. 2022. PMID: 35935884 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources